Clinical Trials Browser

Phase 2/3 × Prostatic Neoplasms × Zoledronic Acid × Clear all

NCT00268476 2023-04-18

STAMPEDE

Phase 2/3 Active not recruiting

11,992 enrolled

Prostatic Neoplasms

NCT01006395 2019-07-05

Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

Phase 2/3 Completed

Insulin Resistance, Prostatic Neoplasms